SBSandra Baumann

Sandra Baumann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandra Baumann has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Christian Meier

    Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland

    2 shared publications
  • Cyril Traechslin

    Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland

    2 shared publications
  • Leticia Grize

    Swiss Tropical and Public Health Institute and University of Basel, Basel, Switzerland

    2 shared publications
  • Lilian Sewing

    Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland

    2 shared publications
  • Marius Kraenzlin

    Endocrine clinic and laboratory, Basel, Switzerland

    2 shared publications
  • Wilma Verhagen-Kamerbeek

    Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland

    2 shared publications

Latest Publications

  • Open Access

    Correction to: Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls

    by Sandra Baumann, Lilian Sewing, Cyril Traechslin, Wilma Verhagen-Kamerbeek, Leticia Grize, Marius Kraenzlin, Christian Meier

  • Open Access

    Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls

    by Sandra Baumann, Lilian Sewing, Cyril Traechslin, Wilma Verhagen-Kamerbeek, Leticia Grize, Marius Kraenzlin, Christian Meier

    Pentosidine (PEN), a surrogate marker of advanced glycation end-product formation, reflects increased non-enzymatic cross-linking in bone collagen, which is thought to be an important determinant of bone fragility in type 2 diabetes mellitus (T2DM). We aimed to investigate serum concentrations of PEN in patients with T2DM and controls without T2DM and to examine its relationship with bone parameters and metabolic state such as glycaemic control, insulin resistance and body weight. In a cross-sectional study-design, data from postmenopausal women and men with T2DM ( n = 110) and controls without T2DM ( n = 111) were evaluated. Serum PEN was measured using an ELISA-based assay (CSB-E09415h, Cusabio). In addition, biochemical markers of glucose metabolism and bone turnover markers were measured. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry. After adjustment for age, gender and body mass index (BMI), serum PEN was significantly higher in patients with T2DM compared to controls ( p = 0.02) and most prominently in women with T2DM ( p = 0.09). We found a strong association of serum PEN concentrations with BMI in the entire study population ( R = 0.43, p < 0.001) as well as in patients with T2DM ( R = 0.28, p < 0.01). While bone turnover markers were significantly decreased, and BMD increased in patients with T2DM, only weak or no associations were observed between these skeletal surrogate markers and serum PEN. We conclude that serum PEN is strongly associated with BMI with highest levels in obese women with T2DM. Adjustment for patient’s weight is needed when evaluating serum PEN levels in patients with T2DM. Clinical Trial Information: NCT02551315.